Skip to main content
main-content

Oncology

ASCO 2019

medwireNews was at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA, bringing you expert video interviews.

Expert interviews

04-06-2019 | Breast cancer | Video

ASCO 2019: Low-fat diet linked to reduced risk of breast cancer mortality

Rowan Chlebowski discusses the latest update from the Women’s Health Initiative Dietary Modification clinical trial showing the positive impact of a healthy diet on the risk of breast cancer death in postmenopausal women. He also touches upon how the metabolic syndrome may modify this risk (5:52).

04-06-2019 | Prostate cancer | Video

ASCO 2019: Enzalutamide addition prolongs survival in metastatic CSPC setting

Ian Davis takes us through the potentially practice-changing results of the phase III ENZAMET trial evaluating the addition of enzalutamide to standard of care in men with castration-sensitive prostate cancer (3:04).

03-06-2019 | Gastrointestinal cancer | Video

ASCO 2019: Olaparib maintenance improves BRCA1/2-positive pancreatic cancer outcomes

Hedy Kindler presents the phase III POLO trial of maintenance therapy with the PARP inhibitor olaparib in metastatic pancreatic cancer patients harbouring germline mutations in BRCA1 or BRCA2 (3:47).

03-06-2019 | Gastrointestinal cancer | Video

ASCO 2019: Low-dose chemotherapy a valid option for older gastro-oesophageal cancer patients

Peter Hall reports on the GO2 trial that aimed to optimise chemotherapy with oxaliplatin and capecitabine in elderly and frail individuals with advanced gastro-oesophageal cancer (1:40).

02-06-2019 | Breast cancer | Video

ASCO 2019: Ribociclib addition boosts OS in premenopausal advanced breast cancer patients

Sara Hurvitz summarises the findings of the phase III MONALEESA-7 trial investigating the addition of ribociclib to endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer (3:21).

02-06-2019 | Prostate cancer | Video

ASCO 2019: TITAN shows survival benefit with apalutamide in metastatic CSPC

Anders Bjartell outlines the main results of the placebo-controlled TITAN trial of apalutamide in men with castration-sensitive prostate cancer receiving androgen deprivation therapy (2:19).

Meta-analysis supports MRI plus targeted biopsy for prostate cancer diagnosis

Man in scanner

Prebiopsy multiparametric magnetic resonance imaging plus targeted biopsy is associated with increased detection of clinically significant prostate cancer versus ultrasonography-guided systematic biopsy alone, study data show.

HIV infection associated with worse prostate cancer outcomes

Blood samples_HIV+

Older individuals with HIV and prostate cancer have worse outcomes than corresponding cancer patients without HIV, according to a large database study from the USA.

Erdafitinib shows promising efficacy in advanced urothelial carcinoma

Urothelial carcinoma

The pan-FGFR inhibitor erdafitinib could be a treatment option for previously treated patients with locally advanced or metastatic urothelial carcinoma harboring FGFR aberrations, suggest phase II trial results.

Local ablative therapy–pembrolizumab benefit suggested for metastatic NSCLC

Lung cancer illustration

Data from two phase II studies published in JAMA Oncology lend support to the sequential use of local ablative therapy and PD-1 blockade in patients with metastatic non-small-cell lung cancer.

Latest news

15-08-2019 | Oncology | News | Article

Gemcitabine–eribulin shows promise for cisplatin-ineligible urothelial carcinoma

Phase II study data suggest favorable treatment response and survival with first-line gemcitabine–eribulin in cisplatin-ineligible patients with metastatic urothelial carcinoma.

14-08-2019 | Oncology | News | Article

Nivolumab shows long-term clinical efficacy in Japanese patients with advanced NSCLC

Pooled long-term results from two multicenter phase II studies indicate that nivolumab is efficacious in Japanese patients with previously treated, stage IIIB/IV squamous or nonsquamous non-small-cell lung cancer.

12-08-2019 | Oncology | News | Article

Individuals with autoimmune disease ‘good candidates’ for cancer immunotherapy

A French database analysis lends further support for the use immune checkpoint inhibitors for cancer in patients with pre-existing autoimmune disease.

09-08-2019 | Prostate cancer | News | Article

‘Superior’ detection of biochemical recurrence with PSMA PET–CT

68Ga-prostate-specific membrane antigen-11 should be the “tracer of choice” for PET–CT to detect the postoperative biochemical recurrence of prostate cancer, say researchers who conducted a comparative imaging trial.

Real-World Chemotherapy PDAC Outcomes Characterised

Observational data provide information on the use and success of chemotherapy and surgery for borderline resectable or locally advanced pancreatic ductal adenocarcinoma

Read the full story on ESMO's oncologyPRO educational website (for registered ESMO members).





Twitter Icon Follow medwireNews

Click here
Image Credits